Pulmonary Arterial Hypertension in Human Immunodeficiency Virus Infection

References

• . Barst RJ, McGoon M, Torbicki A, . Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43(12 suppl S):40S–47S
   Web of Science ®Google Scholar
• . World Health Organization, United Nations Joint Program in HIV/AIDS. AIDS Epedemic Update. Geneva, Switzerland:World Health Organization; 2006
   Google Scholar
• . Kim KK, Factor SM. Membranoproliferative glomerulonephritis and plexogenic pulmonary arteriopathy in a homosexual man with acquired immunodeficiency syndrome. Hum Pathol. 1987;18(12):1293–1296
   PubMed Web of Science ®Google Scholar
• . Anderson DW, Virmani R, Reilly JM, . Prevalent myocarditis at necropsy in the acquired immunodeficiency syndrome. J Am Coll Cardiol. 1988;11(4):792–799
   PubMed Web of Science ®Google Scholar
• . Goldsmith GH Jr, Baily RG, Brettler DB, . Primary pulmonary hypertension in patients with classic hemophilia. Ann Intern Med. 1988;108(6):797–799
   PubMed Web of Science ®Google Scholar
• . Simonneau G, Galie N, Rubin LJ, . Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43(12 suppl S):5S–12S
   Web of Science ®Google Scholar
• . Simonneau G, Robbins IM, Beghetti M, . Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54:S43–S54
   PubMed Web of Science ®Google Scholar
• . Himelman RB, Dohrmann M, Goodman P, . Severe pulmonary hypertension and cor pulmonale in the acquired immunodeficiency syndrome. Am J Cardiol. 1989;64(19):1396–1399
   PubMed Web of Science ®Google Scholar
• . Sitbon O, Lascoux-Combe C, Delfraissy JF, . Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med. 2008;177:108–113
   PubMed Web of Science ®Google Scholar
• . Humbert M, Sitbon O, Chaouat A, . Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173(9):1023–1030
   PubMed Web of Science ®Google Scholar
• . Pellicelli AM, Barbaro G, Palmieri F, . Primary pulmonary hypertension in HIV patients: a systematic review. Angiology. 2001;52(1):31–41
   PubMed Web of Science ®Google Scholar
• . Mesa RA, Edell ES, Dunn WF, Edwards WD. Human immunodeficiency virus infection and pulmonary hypertension: two new cases and a review of 86 reported cases. Mayo Clin Proc. 1998;73(1):37–45
   PubMed Web of Science ®Google Scholar
• . Sitbon O. HIV-related pulmonary arterial hypertension: clinical presentation and management. AIDS. 2008;22( suppl 3):S55–S62
   PubMed Web of Science ®Google Scholar
• . Mehta NJ, Khan IA, Mehta RN, Sepkowitz DA. HIV-related pulmonary hypertension: analytic review of 131 cases. Chest. 2000;118:1133–1141
   PubMed Web of Science ®Google Scholar
• . D'Alonzo GE, Barst RJ, Ayres SM, . Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343–349
   PubMed Web of Science ®Google Scholar
• . Mette SA, Palevsky HI, Pietra GG, . Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy. Am Rev Respir Dis. 1992;145(5):1196–1200
   PubMed Web of Science ®Google Scholar
• . Nunes H, Humbert M, Sitbon O, . Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2003;167:1433–1439
   PubMed Web of Science ®Google Scholar
• . Morse JH, Barst RJ, Itescu S, . Primary pulmonary hypertension in HIV infection: an outcome determined by particular HLA class II alleles. Am J Respir Crit Care Med. 1996;153:1299–1301
   PubMed Web of Science ®Google Scholar
• . Rosenberg ZF, Fauci AS. Immunopathogenic mechanisms of HIV infection: cytokine induction of HIV expression. Immunol Today. 1990; 11(5):176–180
   PubMedGoogle Scholar
• . Ascherl G, Hohenadl C, Schatz O, . Infection with human immunodeficiency virus-1 increases expression of vascular endothelial cell growth factor in T cells: implications for acquired immunodeficiency syndrome-associated vasculopathy. Blood. 1999;93(12):4232–4241
   PubMed Web of Science ®Google Scholar
• . Humbert M, Monti G, Fartoukh M, . Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J. 1998;11(3):554–559
   PubMed Web of Science ®Google Scholar
• . Degano B, Sitbon O, Simonneau G. Pulmonary arterial hypertension and HIV infection. Semin Respir Crit Care Med. 2009;30(4):440–447
   PubMed Web of Science ®Google Scholar
• . Kanmogne GD, Primeaux C, Grammas P. Induction of apoptosis and endothelin-1 secretion in primary human lung endothelial cells by HIV–1 gp120 proteins. Biochem Biophys Res Commun. 2005;333(4):1107–1115
   PubMed Web of Science ®Google Scholar
• . Laney AS, De Marco T, Peters JS, . Kaposi sarcoma-associated herpesvirus and primary and secondary pulmonary hypertension. Chest. 2005;127(3):762–767
   PubMed Web of Science ®Google Scholar
• . Montani D, Marcelin AG, Sitbon O, . Human herpes virus 8 in HIV and non-HIV infected patients with pulmonary arterial hypertension in France. AIDS. 2005;19(11):1239–1240
   PubMed Web of Science ®Google Scholar
• . Swain SD, Han S, Harmsen A, Shampeny K, Harmsen AG. Pulmonary hypertension can be a sequela of prior Pneumocystis pneumonia. Am J Pathol. 2007;171(3):790–799
   PubMed Web of Science ®Google Scholar
• . Ruchelli ED, Nojadera G, Rutstein RM, . Pulmonary veno-occlusive disease. Another vascular disorder associated with human immunodeficiency virus infection? Arch Pathol Lab Med. 1994;118(6):664–666
   PubMed Web of Science ®Google Scholar
• . Fisher MR, Forfia PR, Chamera E, . Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med. 2009;179(7):615–621
   PubMed Web of Science ®Google Scholar
• . McGoon M, Gutterman D, Steen V, . Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126( 1 suppl):14S–34S
   PubMed Web of Science ®Google Scholar
• . Rubin LJ, Badesch DB. Evaluation and management of the patient with pulmonary arterial hypertension. Ann Intern Med. 2005;143:282–292
   PubMed Web of Science ®Google Scholar
• . Degano B, Yaici A, Le Pavec J, . Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur Respir J. 2009;33(1):92–98
   PubMed Web of Science ®Google Scholar
• . Barst RJ, Gibbs JS, Ghofrani HA, . Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54( 1 suppl):S78–S84
   PubMed Web of Science ®Google Scholar
• . Alam S, Palevsky HI. Standard therapies for pulmonary arterial hypertension. Clin Chest Med. 2007;28(1):91–115
   PubMed Web of Science ®Google Scholar
• . Hoeper MM, Galie N, Murali S, . Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2002;165(3):341–344
   PubMed Web of Science ®Google Scholar
• . Frank H, Mlczoch J, Huber K, Schuster E, Gurtner HP, Kneussl M. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest. 1997;112(3):714–721
   PubMed Web of Science ®Google Scholar
• . Matta F, Yaekoub AY, Stein PD. Human immunodeficiency virus infection and risk of venous thromboembolism. Am J Med Sci. 2008;336(5):402–406
   PubMed Web of Science ®Google Scholar
• . Sitbon O, Jais X, Loos V, . Acute vasodilator responsiveness and long term response to calcium channel blockers in different forms of pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;169:A120
   PubMedGoogle Scholar
• . Glesby MJ, Aberg JA, Kendall MA, .; Adult AIDS Clinical Trials Group A5159 Protocol Team. Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. Clin Pharmacol Ther. 2005;78(2):143–153
   PubMed Web of Science ®Google Scholar
• . Rich S, Seidlitz M, Dodin E, . The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest. 1998;114(3):787–792
   PubMed Web of Science ®Google Scholar
• . Speich R, Jenni R, Opravil M, . Regression of HIV-associated pulmonary arterial hypertension and long-term survival during antiretroviral therapy. Swiss Med Wkly. 2001;131(45–46):663–665
   PubMed Web of Science ®Google Scholar
• . Zuber JP, Calmy A, Evison JM, . Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis. 2004;38(8):1178–1185
   PubMed Web of Science ®Google Scholar
• . Torre D, Pugliese A. Impact of antiretroviral therapy among HIV-1-infected patients with pulmonary hypertension. Clin Infect Dis. 2004; 39(10):1549–1550
   PubMed Web of Science ®Google Scholar
• . Reinsch N, Buhr C, Krings P, . Effect of gender and highly active antiretroviral therapy on HIV-related pulmonary arterial hypertension: results of the HIV-HEART Study. HIV Med. 2008;9(7):550–556
   PubMed Web of Science ®Google Scholar
• . Hebert VY, Crenshaw BL, Romanoff RL, Ekshyyan VP, Dugas TR. Effects of HIV drug combinations on endothelin-1 and vascular cell proliferation. Cardiovasc Toxicol. 2004;4(2):117–131
   PubMedGoogle Scholar
• . Wang X, Chai H, Lin PH, . Roles and mechanisms of human immunodeficiency virus protease inhibitor ritonavir and other anti-human immunodeficiency virus drugs in endothelial dysfunction of porcine pulmonary arteries and human pulmonary artery endothelial cells. Am J Pathol. 2009;174(3):771–781
   PubMed Web of Science ®Google Scholar
• . Galie N, Torbicki A, Barst R, .; Task Force. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J. 2004;25(24):2243–2278
   PubMed Web of Science ®Google Scholar
• . Badesch DB, Abman SH, Ahearn GS, . Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126:35S–62S
   PubMed Web of Science ®Google Scholar
• . Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest. 2007;131(6):1917–1928
   PubMed Web of Science ®Google Scholar
• . Stricker H, Domenighetti G, Mombelli G. Prostacyclin for HIV-associated pulmonary hypertension. Ann Intern Med. 1997;127(11):1043
   PubMed Web of Science ®Google Scholar
• . Ghofrani HA, Friese G, Discher T, . Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension. Eur Respir J. 2004;23(2):321–326
   PubMed Web of Science ®Google Scholar
• . Aguilar RV, Farber HW. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med. 2000;162(5):1846–1850
   PubMed Web of Science ®Google Scholar
• . Cea-Calvo L, Escribano Subias P, Tello de Menesses R, . Treatment of HIV-associated pulmonary hypertension with treprostinil. Rev Esp Cardiol. 2003;56(4):421–425
   PubMed Web of Science ®Google Scholar
• . Rubin LJ, Badesch DB, Barst RJ, . Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346(12):896–903
   PubMed Web of Science ®Google Scholar
• . Sitbon O, Gressin V, Speich R, . Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;170(11):1212–1217
   PubMed Web of Science ®Google Scholar
• . Zacà V, Metra M, Danesi R, Lombardi C, Verzura G, Dei Cas L. Successful switch to sitaxsentan in a patient with HIV-related pulmonary arterial hypertension and late intolerance to nonselective endothelin receptor blockade. Ther Adv Respir Dis. 2009;3(1):11–14
   PubMedGoogle Scholar
• . Watanabe H, Ohashi K, Takeuchi K, . Sildenafil for primary and secondary pulmonary hypertension. Clin Pharmacol Ther. 2002; 71(5):398–402
   PubMed Web of Science ®Google Scholar
• . Ghofrani HA, Wiedemann R, Rose F, . Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet. 2002;360(9337):895–900
   PubMed Web of Science ®Google Scholar
• . Simonneau G, Rubin LJ, Galie N, . Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008;149(8):521–530
   PubMed Web of Science ®Google Scholar
• . Ghofrani HA, Rose F, Schermuly RT, . Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol. 2003;42(1):158–164
   PubMed Web of Science ®Google Scholar
• . Wilkins MR, Wharton J, Grimminger F, Ghofrani HA. Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. Eur Respir J. 2008;32(1):198–209
   PubMed Web of Science ®Google Scholar
• . Schumacher YO, Zdebik A, Huonker M, . Sildenafil in HIV-related pulmonary hypertension. AIDS. 2001;15:1747–1748
   PubMed Web of Science ®Google Scholar
• . Carlsen J, Kjeldsen K, Gerstoft J. Sildenafil as a successful treatment of otherwise fatal HIV-related pulmonary hypertension. AIDS. 2002;16(11):1568–1569
   PubMed Web of Science ®Google Scholar
• . Wong AR, Rasool AH, Abidin NZ, Noor AR, Quah BS. Sildenafil as treatment for Human Immunodeficiency Virus-related pulmonary hypertension in a child. J Paediatr Child Health. 2006;42(3):147–148
   PubMed Web of Science ®Google Scholar
• . Muirhead GJ, Wulff MB, Fielding A, Kleinermans D, Buss N. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol. 2000;50(2):99–107
   PubMed Web of Science ®Google Scholar
• . Croom KF, Curran MP. Sildenafil: a review of its use in pulmonary arterial hypertension. Drugs. 2008;68(3):383–397
   PubMed Web of Science ®Google Scholar
• . McLaughlin VV, Oudiz RJ, Frost A, . Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174(11):1257–1263
   PubMed Web of Science ®Google Scholar
• . Stiebellehner L, Petkov V, Vonbank K, . Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. Chest. 2003;123(4):1293–1295
   PubMed Web of Science ®Google Scholar
• . International guidelines for the selection of lung transplant candidates. The American Society for Transplant Physicians (ASTP)/American Thoracic Society(ATS)/European Respiratory Society(ERS)/International Society for Heart and Lung Transplantation(ISHLT). Am J Respir Crit Care Med. 1998;158(1):335–339
   PubMedGoogle Scholar
• . Doyle RL, McCrory D, Channick RN, . Surgical treatments/interventions for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126( 1 suppl):63S–71Ss
   PubMed Web of Science ®Google Scholar
• . emc Medicines. Tracleer (bosentan) 125 mg film-coated tablets. http://emc.medicines.org.uk/document.aspx?documentId=17443#contraindications. Accessed August 26, 2009
   Google Scholar
• . Revatio [package insert]. New York, NY: Pfizer, Inc; May 2009. http://www.media.pfizer.com/files/products/uspi_revatio.com. Accessed August 26, 2009
   Google Scholar
• . emc Medicines. Tracleer (bosentan) 125 mg film-coated tablets. http://emc.medicines.org.uk/medicine/20423/SPC/Tracleer+(bosentan)+125mg+film-coated+tablets. Accessed August 26, 2009
   Google Scholar